Revolution Medicines said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for daraxonrasib on Thursday. That endorsement pushes the life-extending treatment a step closer to patients across the 27-nation bloc, and the European Commission is expected to render its verdict within the next few months.
Pancreatic cancer has resisted progress for years, and daraxonrasib is one of the most notable advances in a long time. In a final-stage trial, patients with an especially aggressive form lived for nearly twice as long as is typical. The drug is among the first to broadly and successfully go after RAS, a tumor-driving protein mutated in most pancreatic cancers, using an inventive "molecular glue" approach that neutralizes the target.
When financial news can affect big decisions, stay informed with our free Market Briefs newsletter that summarizes it all
This is not a cure, and tumors tend to adapt over time. Reported side effects have included skin rashes and sores in the mouth. In the US, the medicine is sold as Rasonque with a list price above $475,000 per year. A survey of analysts by Bloomberg suggests global yearly sales could ultimately top $9 billion, a reminder that breakthroughs in tough cancers can drive both patient impact and significant revenue.
Because you value clear, concise market context, sign up for free Market Briefs to read it in minutes
